Gsk (GLAXF) Receivables (2009 - 2026)

Gsk's Receivables history runs 18 years deep, the most recent figure standing at $10.5 billion for Q1 2026.

• In Q1 2026, Receivables rose 17.61% year-over-year to $10.5 billion; the TTM figure through Mar 2026 stood at $10.5 billion (up 17.61% YoY), while the FY2025 annual figure was $11.4 billion, up 15.55% from the prior year.
• Receivables was $10.5 billion for Q1 2026 at Gsk, down from $11.5 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $18.4 billion in Q1 2022 to a low of $8.1 billion in Q2 2022.
• Historically, Receivables has averaged $10.1 billion across 5 years, with a median of $9.7 billion in 2022.
• The sharpest annual moves came in 2022 and 2023: Receivables jumped 106.03% in 2022, then sank 54.97% in 2023.
• A 5-year view of Receivables shows it stood at $9.7 billion in 2022, then grew by 7.75% to $10.5 billion in 2023, then slipped by 5.63% to $9.9 billion in 2024, then rose by 16.1% to $11.5 billion in 2025, then decreased by 8.78% to $10.5 billion in 2026.
• The last three Receivables figures came in at $10.5 billion (Q1 2026), $11.5 billion (Q4 2025), and $10.7 billion (Q3 2025), per Business Quant data.